α-Conotoxin ImI is a disulfide-rich, cysteine-constrained peptide from cone snail venom targeting nicotinic receptor subtypes in research settings. Its compact fold and defined loop architecture enable high-affinity binding. Researchers examine structure-activity relationships via NMR and mutagenesis. Applications include ion-channel mapping, neurotoxin motif analysis, and conformational-stability studies.
CAT No: PI-024
CAS No:156467-85-5
Synonyms/Alias:alpha-Conotoxin imi;alpha-Ctx-imi;156467-85-5;Gly-cys-cys-ser-asp-pro-arg-cys-ala-trp-arg-cys-NH2;DTXSID10166085;Glycyl-cysteinyl-cysteinyl-seryl-asparginyl-prolyl-arginyl-cysteinyl-alanyl-tryptophyl-arginyl-cysteinamide;L-Cysteinamide, glycyl-L-cysteinyl-L-cysteinyl-L-seryl-L-alpha-aspartyl-L-prolyl-L-arginyl-L-cysteinyl-L-alanyl-L-tryptophyl-L-arginyl-, cyclic (2-8),(3-12)-bis(disulfide);alpha-CTX IMI;CHEMBL500076;DTXCID7088576;
Alpha-conotoxin ImI is a specialized peptide derived from the venom of the marine cone snail species Conus imperialis, recognized for its unique ability to selectively target and modulate specific subtypes of nicotinic acetylcholine receptors (nAChRs). Distinguished by its compact, disulfide-rich structure, this conotoxin exhibits high affinity and specificity for α7 nAChRs, making it a powerful molecular tool in neuropharmacological research. Its sequence and three-dimensional conformation enable precise interaction with receptor binding sites, allowing researchers to dissect the functional roles of these receptors in various physiological and pathological processes. The stability and bioactivity of alpha-conotoxin ImI, combined with its synthetic accessibility, have positioned it as a valuable asset in the exploration of neuronal signaling pathways, receptor pharmacology, and toxin-receptor interactions at the molecular level.
Neuropharmacology research: Alpha-conotoxin ImI is extensively utilized in neuropharmacological studies to investigate the distribution, function, and pharmacological properties of nicotinic acetylcholine receptors, particularly the α7 subtype. By selectively inhibiting these receptors, researchers can delineate their involvement in neurotransmission, synaptic plasticity, and neurodevelopmental processes. The use of this conotoxin in electrophysiological assays and receptor binding studies facilitates the characterization of receptor subtypes and the identification of novel modulators or antagonists, providing deeper insight into neuronal communication and the molecular underpinnings of neurological disorders.
Ion channel studies: In the realm of ion channel research, alpha-conotoxin ImI serves as a precise molecular probe for dissecting the mechanisms of ligand-gated ion channel activation and inhibition. Its selectivity enables the isolation and functional analysis of α7 nAChRs within complex cellular systems, aiding in the understanding of ion flux, membrane potential changes, and downstream signaling cascades. Researchers employ this peptide in patch-clamp experiments, fluorescence-based assays, and structure-function analyses to unravel the biophysical properties and conformational dynamics of nAChRs, advancing the field of ion channel pharmacology.
Structure-activity relationship (SAR) analysis: The defined sequence and structural features of alpha-conotoxin ImI make it an exemplary model for structure-activity relationship studies. Scientists modify its amino acid sequence or disulfide bonding patterns to assess the impact on receptor binding affinity, selectivity, and functional potency. These SAR investigations contribute to the rational design of novel conotoxin analogs with enhanced specificity or altered pharmacological profiles, supporting the development of new molecular probes and potential therapeutic candidates targeting cholinergic signaling pathways.
Receptor mapping and imaging: Alpha-conotoxin ImI is also employed in receptor mapping and imaging studies aimed at visualizing the spatial distribution and density of α7 nAChRs in tissues and cell preparations. By conjugating the peptide with fluorescent tags or radiolabels, researchers can track receptor localization in neuronal circuits, assess changes in receptor expression under different experimental conditions, and correlate receptor density with functional outcomes. These applications are crucial for elucidating receptor involvement in neurobiological processes and for validating targets in drug discovery programs.
Toxin-receptor interaction modeling: The unique interaction between alpha-conotoxin ImI and its target receptors provides an ideal system for computational modeling and structural biology investigations. Molecular docking, molecular dynamics simulations, and crystallographic studies leveraging this peptide yield detailed insights into the binding interfaces, conformational changes, and energetic landscapes governing toxin-receptor recognition. These findings inform the broader understanding of ligand specificity and allosteric modulation within the nAChR family, fostering innovation in the design of receptor-targeted ligands and biologically active peptides.
Peptide engineering and synthetic biology: In the context of peptide engineering, alpha-conotoxin ImI serves as a scaffold for the generation of engineered peptides with tailored pharmacological profiles. Its well-characterized structure and receptor selectivity inspire the design of synthetic analogs or chimeric peptides aimed at targeting diverse ion channels or neurotransmitter receptors. By leveraging techniques such as solid-phase peptide synthesis, site-directed mutagenesis, and combinatorial chemistry, researchers harness the molecular blueprint of this conotoxin to expand the repertoire of bioactive peptides available for research in neurobiology, pharmacology, and synthetic biology.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More